Trastuzumab administration during pregnancy: A systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 137, Issue 2, 2013, Pages 349-357

  Zagouri, Flora ^a   Sergentanis, Theodoros N ^b   Chrysikos, Dimosthenis ^b   Papadimitriou, Christos A ^b   Dimopoulos, Meletios Athanassios ^b   Bartsch, Rupert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Oligohydramnios; Pregnancy; Trastuzumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; GOSERELIN; IBANDRONIC ACID; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANHYDRAMNIOS; ATELECTASIS; BIRTH WEIGHT; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HEART EJECTION FRACTION; HUMAN; INTRADUCTAL CARCINOMA; KIDNEY FAILURE; LUNG HYPOPLASIA; MAJOR CLINICAL STUDY; META ANALYSIS; NEWBORN; OLIGOHYDRAMNIOS; OVERALL SURVIVAL; PREGNANCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; VAGINA BLEEDING; ENVIRONMENTAL EXPOSURE; INFANT MORTALITY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIRTH WEIGHT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS;

MLCS; MLOWN;

EID: 84880109920     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2368-y     Document Type: Review

References (40)

1. Pentheroudakis G, Orecchia R, Hoekstra HJ et al (2010) Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v266-v273
2. Mir O, Berveiller P, Ropert S et al (2008) Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 19:607-613
3. Howlader N, Noone AM, Krapcho M, et al (2011) SEER cancer statistics review, 1975-2008. National Cancer Institute. Bethesda. http://seer.cancer.gov/ csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site
4. Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
6. Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-3357
7. Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149-156
8. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264-271
9. NCCN Clinical Practice Guidelines in Oncology (2012) Breast cancer, version 2.2012. www.nccn.com
10. Azim HA Jr, Azim H, Peccatori FA (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 6:821-826
11. Abusief ME, Missmer SA, Ginsburg ES et al (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:791-798
12. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-e34
13. Gottschalk I, Berg C, Harbeck N et al (2011) Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report und review of the current literature. Breast Care (Basel) 6:475-478
14. El-Safadi S, Wuesten O, Muenstedt K (2012) Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res 38:589-592
15. Mandrawa CL, Stewart J, Fabinyi GC et al (2011) A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 51:372-376
16. Goodyer MJ, Ismail JR, O'Reilly SP et al (2009) Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2:9329
17. Beale JM, Tuohy J, McDowell SJ (2009) Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 201:e13-e14
18. Weber-Schoendorfer C, Schaefer C (2008) Trastuzumab exposure during pregnancy. Reprod Toxicol 25:390-391; author reply 392
19. Pant S, Landon MB, Blumenfeld M et al (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26:1567-1569
20. Witzel ID, Müller V, Harps E et al (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19:191-192
21. Sekar R, Stone PR (2007) Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 110:507-510
22. Shrim A, Garcia-Bournissen F, Maxwell C et al (2007) Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy- Case report and updated literature review. Reprod Toxicol 23:611-613
23. Bader AA, Schlembach D, Tamussino KF et al (2007) Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8:79-81
24. Waterston AM, Graham J (2006) Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 24:321-322
25. Fanale MA, Uyei AR, Theriault RL et al (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6:354-356
26. Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105:642-643
27. Azim HA Jr, Peccatori FA, Liptrott SJ et al (2009) Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6:367-370
28. Warraich Q, Smith N (2009) Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 29:147-148
29. Roberts NJ, Auld BJ (2010) Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy. J R Soc Med 103:157-159
30. Azim HA Jr, Peccatori FA, Pavlidis N (2010) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 36:101-109
31. Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 83:234-238
32. Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer [Epub Ahead of print]
33. Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328-344
34. Malek A (2003) Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 21:3362-3364
35. Kilpatrick SJ (1997) Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Clin Obstet Gynecol 40:328-336
36. Vanderheyden T, Kumar S, Fisk NM (2003) Fetal renal impairment. Semin Neonatol 8:279-289
37. Goodyer PR, Cybulsky A, Goodyer C (1993) Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol 7:612-615
38. Jokhi PP, King A, Loke YW (1994) Reciprocal expression of epidermal growth factor receptor (EGF-R) and c-erbB2 by non-invasive and invasive human trophoblast populations. Cytokine 6:433-442
39. Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398
40. Azim HA Jr, Metzger-Filho O, de Azambuja E et al (2012) Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat 133:387-391